MelanA/MART 1 and gp100 vaccines: GZMO will enroll an additional 8 patients in a dose-escalation U.S. Phase I/II trial after completing enrollment of an intende

Genzyme Molecular Oncology (GZMO), Framingham, Mass. Product: MelanA/MART 1 and gp100 vaccines Business: Cancer Therapeutic category: Immune stimulation Target: MelanA/MART 1 and gp100 antigens Descri...